MARKET

ADRO

ADRO

Aduro Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.660
-0.040
-1.48%
After Hours: 2.590 -0.07 -2.63% 17:31 07/09 EDT
OPEN
2.690
PREV CLOSE
2.700
HIGH
2.750
LOW
2.590
VOLUME
596.11K
TURNOVER
--
52 WEEK HIGH
4.040
52 WEEK LOW
0.9011
MARKET CAP
215.03M
P/E (TTM)
-3.2129
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADRO stock price target is 3.750 with a high estimate of 3.750 and a low estimate of 3.750.

EPS

ADRO News

More
Hedge Funds Are Warming Up To Aduro BioTech Inc (ADRO)
Insider Monkey · 5d ago
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy
GlobeNewswire · 06/24 13:15
Dosing underway in Aduro Bio's BION-1301 study for kidney disease
Seeking Alpha - Article · 06/24 13:10
Aduro Biotech Announces First Patient Dosed In Phase 1 Study Of BION-1301 In IgA Nephropathy
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical
Benzinga · 06/24 12:16
MGI, WWR, NNA and ADRO among midday movers
Seeking Alpha - Article · 06/02 16:46
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenax Therapeutics Inc (NASDAQ: TENX) shares climbed 42.3% to $2.07 after the company reported results from its Phase 2 trial of Levosimendan. The trial demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures.
Benzinga · 06/02 16:21
A Peek Into Aduro Biotech's P/E Ratio
Benzinga · 06/02 15:41
A Peek Into Aduro Biotech's P/E Ratio
 
Benzinga · 06/02 14:41

Industry

Biotechnology & Medical Research
-0.44%
Pharmaceuticals & Medical Research
-0.78%

Hot Stocks

Symbol
Price
%Change

About ADRO

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
More

Webull offers kinds of Aduro BioTech Inc stock information, including NASDAQ:ADRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADRO stock methods without spending real money on the virtual paper trading platform.